ArticleArchives of medical science : AMS2018
Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis.
Article in Archives of medical science : AMS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis.Frontiers in nutrition · 2025Pooled it
- FIB-4 index associated with mortality risk of patients with systemic lupus erythematosus: a large retrospective cohort study.Archives of medical science : AMS · 2026Article
- The Maternal and Fetal Consequences of Metabolic Dysfunction-Associated Fatty Liver Disease and Gestational Diabetes Mellitus.Nutrients · 2025Review
- Effects of metformin use on aneurysmal subarachnoid hemorrhage outcomes.Acta neurochirurgica · 2025Article
- Epidemiology of metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Review
- Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index.Journal of epidemiology and global health · 2024Article
- The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.Nature communications · 2024Article
- The Cardiac-Kidney-Liver (CKL) syndrome: the "real entity" of type 2 diabetes mellitus.Archives of medical science : AMS · 2024Article
- A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation.Biochemistry and biophysics reports · 2023Review
- Serum Metabolites Are Associated With HFpEF in Biopsy-Proven Nonalcoholic Fatty Liver Disease.Journal of the American Heart Association · 2023Article
- Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.Frontiers in endocrinology · 2023Article
- Positron emission tomographic studies of the association between atherogenesis and aortitis among psoriatic patients.Archives of medical science : AMS · 2023Article
- Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.Journal of cardiovascular development and disease · 2022Review
- Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis.Healthcare (Basel, Switzerland) · 2022Article
- Article
- The effect of camelina oil (α-linolenic acid) and canola oil (oleic acid) on lipid profile, blood pressure, and anthropometric parameters in postmenopausal women.Archives of medical science : AMS · 2021Article
- KIR2DL2/S2 and KIR2DS5 in alcoholic cirrhotic patients undergoing liver transplantation.Archives of medical science : AMS · 2021Article
- Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.Nutrients · 2020Review
- Genetic Variants and Haplotypes inDNA and cell biology · 2020Article
- Analysis of Risk Factors for Adverse Cardiovascular Events in Elderly Patients with Acute Myocardial Infarction and Non-Alcoholic Fatty Liver Disease (NAFLD).Medical science monitor : international medical journal of experimental and clinical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) refers to fatty infiltration of liver in the absence of significant alcohol intake, use of steatogenic medication, or hereditary disorders. It is a common cause of chronic liver disease with a worldwide estimated prevalence ranging from 6.3% to 33%. The NAFLD is considered a hepatic manifestation of the metabolic syndrome. Insulin resistance and increased oxidative stress are central to pathogenesis of NAFLD, and risk factors include metabolic syndrome, diabetes mellitus, obesity, lack of physical activity, smoking, and high fat diet. NAFLD is associated with higher mortality as compared to the general population with cardiovascular disease being the most common cause of death. The NAFLD is associated with a higher prevalence of subclinical atherosclerosis as evidenced by odds of higher coronary artery calcification, higher average and maximum carotid intima-media thickness. It is also associated with stiff arteries as evidenced by higher cardio-ankle vascular index and higher brachial-ankle pulse wave velocity. Increasing evidence has linked NAFLD with atherosclerotic cardiovascular diseases. The NAFLD is associated with a higher prevalence of coronary artery disease (CAD), more severe CAD, poor coronary collateral development, and higher incidence of coronary events. The NAFLD is also associated with ischemic stroke. Studies have shown that the association between NAFLD and atherosclerotic cardiovascular diseases is independent of shared risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.